Needham & Company Starts Hyperion Therapeutics (HPTX) at Buy; Commercial Opportunity for Navicti
Tweet Send to a Friend
Needham & Company initiates coverage on Hyperion Therapeutics (NASDAQ: HPTX) with a Buy. PT $15.00.
Analyst, Alan Carr, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Alan Carr, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
